Catalog No.
DHC13601
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG4-nd
Clonality
Monoclonal
Target
IL5, B-cell differentiation factor I, IL-5, T-cell replacing factor, TRF, Eosinophil differentiation factor, Interleukin-5
Concentration
1.71 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P05113
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CDP-835, JES1-39D10, SCH55700, CAS: 241473-69-8
Clone ID
Reslizumab
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma, PMID: 32034960
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials, PMID: 25736990
Reslizumab, PMID: 31643704
Reslizumab, PMID: 29999862
Reslizumab (Cinqair) [Internet], PMID: 29356467
Reslizumab in Eosinophilic Asthma: A Review, PMID: 28421429
Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, PMID: 32401603
Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials, PMID: 32066536
Reslizumab in the treatment of severe eosinophilic asthma: an update, PMID: 29554826
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts, PMID: 27018175
Update on reslizumab for eosinophilic asthma, PMID: 26372797
Reslizumab: First Global Approval, PMID: 27125787
Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal, PMID: 29582406
The effectiveness of Reslizumab in severe asthma treatment: a real-world experience, PMID: 31861993
Efficacy of Reslizumab Treatment in Exacerbation-Prone Patients with Severe Eosinophilic Asthma, PMID: 32562877
Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects, PMID: 28683596
Reslizumab in the management of poorly controlled asthma: the data so far, PMID: 27621657
Efficacy of Intravenous Reslizumab in Oral Corticosteroid-Dependent Asthma, PMID: 31626990
Reslizumab: Maintenance treatment for eosinophilic asthma inadequately controlled on corticosteroids, PMID: 27458609
Reslizumab as add-on therapy in patients with refractory asthma, PMID: 32273395
Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma, PMID: 29268638
New treatments for chronic urticaria, PMID: 31446134
Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives, PMID: 30147386
Anti-IL5 therapies for asthma, PMID: 28933516
Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?, PMID: 28344579
Safety of Reslizumab in Uncontrolled Asthma with Eosinophilia: A Pooled Analysis from 6 Trials, PMID: 31404668
Safety of humanized monoclonal antibodies against IL-5 in asthma: focus on reslizumab, PMID: 29486600
Asthma in adults: Principles of treatment, PMID: 31690379
The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis, PMID: 27435534
Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis, PMID: 30217529
Efficacy of Reslizumab for Eosinophilic Esophagitis, PMID: 29985878
Update on new biologics for intractable eosinophilic asthma: impact of reslizumab, PMID: 29780238
Precision medicine in asthma: linking phenotypes to targeted treatments, PMID: 29036018
Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis, PMID: 30533206
Diagnosis and Management of Asthma in Adults: A Review, PMID: 28719697
Effect of intravenously administered reslizumab on spirometric lung age in patients with moderate-to-severe eosinophilic asthma, PMID: 31262379
Reslizumab and mepolizumab for moderate-to-severe poorly controlled asthma: an indirect comparison meta-analysis, PMID: 31686556
Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab, PMID: 30661320
Clinical Outcomes and Health-Care Resource Use Associated With Reslizumab Treatment in Adults With Severe Eosinophilic Asthma in Real-World Practice, PMID: 33333058
Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab, PMID: 28915080
Molecular Targets for Biological Therapies of Severe Asthma, PMID: 33329598
Dupilumab for the treatment of asthma, PMID: 28085503
Efficacy and safety of reslizumab in patients with moderate to severe eosinophilic asthma, PMID: 25578680
Update in Asthma and Airway Inflammation 2018, PMID: 31026407
Biological therapies for eosinophilic asthma, PMID: 29938543
A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma, PMID: 30003833
[Clinical and economic analysis of Reslizumab use in the treatment of patients with severe allergic eosinophilic asthma], PMID: 32598589
Targeted Molecular Therapies in Allergy and Rhinology, PMID: 33138725
Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting β 2-agonists in South Korea, PMID: 30964365
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Modeling of Weight-Based Intravenous Reslizumab Dosing, PMID: 32333684
For research use only. Not for human or drug use.
